CRMD Research Coverage

 

745 Route 202-206, Suite 303
Bridgewater, NJ 08807
Phone: 908-517-9500
Fax: 908-429-4307

CorMedix News Room

Current Articles | RSS Feed RSS Feed

National Securities Issues "Buy" Rating on CorMedix (CRMD)

Posted by Mike Sweeney on Thu, Jul 15, 2010 @ 12:08 PM
  
  
  
  
Add to delicious  delicious  
  
  

National Securities initiated research coverage of CorMedix with a "Buy" rating. National stated:

"We see the Company as ideally positioned at the cardio-renal crossroads; that is, treating kidney diseases and reducing the commonly associated cardiovascular and metabolic complications, in effect, “treating the kidney to treat the heart.” The two products driving the story are Deferiprone for the prevention of contrast induced nephropathy (CIN) in high risk patients and Neutrolin (catheter lock solution) for the prevention of central venous catheter infection and maintenance of catheter function in hemodialysis patients."

National Securities - Cormedix Research Report - PDF

Tags: , , , , , , , , , , , , , ,

Comments

Currently, there are no comments. Be the first to post one!
Post Comment
Name
 *
Email
 *
Website (optional)
Comment
 *

Allowed tags: <a> link, <b> bold, <i> italics

CorMedix (AMEX:CRMD-U)

CorMedix Inc. (AMEX:CRMD-U) is a pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the treatment of cardiac and kidney (cardiorenal) disease.

Cardiorenal disease includes a broad range of inter-related cardiovascular, kidney and metabolic problems which share the common trait of underlying oxidative stress and blood vessel malfunction (endothelial dysfunction).